Please assess the completion status of the following clinical trial:

Trial Title: A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female: 50 years of age or older~* \>5 years since last menses natural or surgical~* have lumbar spine or total hip BMD more that 2.5 SD below the young adult mean, or have lumbar spine or total hip BMD more than 2.0 SD below the young adult female mean value and also have at least one prevalent vertebral body fracture~Exclusion Criteria:~* history of uncontrolled hyperparathyroidism, hyperthyroidism, osteomalacia~* BMI \>32 kg/m~* use of medications within 3 months of starting study drug that impact bone metabolism such as glucocorticoids, estrogens, calcitonin, calcitriol, other bisphosphonates and parathyroid hormone~* hypocalcemia or hypercalcemia of any cause~* markedly abnormal clinical laboratory measurements that are assessed as clinically significant by the investigator

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5 mg Before Breakfast (Type: ACTIVE_COMPARATOR): 5 mg / Immediate-release Risedronate (At Least 30 Minutes Before Breakfast)
- 35 mg After Breakfast (Type: EXPERIMENTAL): 35 mg / Delayed-release Risedronate (Immediately Following Breakfast)
- 35 mg Before Breakfast (Type: EXPERIMENTAL): 35 mg / Delayed-release Risedronate (At Least 30 Minutes Before Breakfast)

Based on this trial design, predict the completion outcome and termination type (if applicable).